CareDx, Inc. CDNA

Full chart Compare
Set alert

Price alert · CDNA

All alert types
77.26 USD -8.60 (-10.02%)

Nov 5, 2026, 1:28 PM EST

76.17 Day range 83.60
15.01 52-week range 88.47
YTD
+310.08%
1 year
+367.39%
Market cap
4.12B
Revenue (ttm)
497.40M
Profit margin
25.86%
EPS (ttm)
2.37
Shares out
52.54M
P/E ratio
33.12
Forward P/E
54.40
YTD return
+310.08%
1-year return
+367.39%
Volume
1.25M
Avg volume
1.30M
Open
83.60
Previous close
85.86
Day's range
76.17 – 83.60
52-week range
15.01 – 88.47
Beta
2.49
Analysts
Buy
Price target
93.50 (+21.0%)
Earnings date
Feb 23, 2027

2Y +55.60 (+242.79%)

255075Jan 25Jun 25Nov 25Apr 26Aug 2678.50

Key statistics

Enterprise value
4.43B
PEG ratio
0.00
Price / sales
9.07
Price / book
9.64
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
39.30%
Free cash flow
130.45M
Total cash
250.48M
Total debt
29.00M
Return on equity
33.04%
Short % of float
13.04%
50-day average
61.49
200-day average
34.31

Financials — quick view

All financials
CDNA Revenue — quarterly 139.36M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CDNA Net income — quarterly 19.29M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CDNA EPS — quarterly 0.37
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

CDNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.3633———
Oct 29, 2026Sep 30, 20260.25480.70+0.45+174.73%
Jul 30, 2026Jun 30, 20260.23210.37+0.14+59.41%
Apr 28, 2026Mar 31, 20260.110.34+0.23+209.09%
Feb 24, 2026Dec 31, 20250.01990.12+0.10+503.02%
Nov 4, 2025Sep 30, 2025-0.081920.0319+0.11+138.94%

Upgrades / downgrades

CDNA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026BTIGmainBuyBuy
Oct 27, 2026BTIGmainBuyBuy
Oct 19, 2026Canaccord GenuitymainBuyBuy
Sep 24, 2026BTIGmainBuyBuy
Sep 2, 2026Canaccord Genuityinit—Buy
Aug 6, 2026BTIGmainBuyBuy

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
caredx.com

News

Your note

Sign in to keep a note on CDNA — it syncs with the Stock Master app.

Insider holders

CDNA insider holders
InsiderRelationLatest transactionDateShares held
BICKERSTAFF GEORGE W IIIDirectorSaleAug 4, 2026134,061
COHEN FREDERICK E. M.D. PH.D.DirectorStock Award(Grant)Jun 11, 2026165,060
GOLDBERG MICHAEL DDirectorStock Award(Grant)Oct 1, 2026153,371
HANNA JOHN WALTER JRChief Executive OfficerSaleJul 15, 2026653,448
JAIN ABHISHEKChief Financial OfficerSaleApr 6, 2025337,418
KENNEDY KEITH SChief Operating OfficerStock Award(Grant)Apr 19, 2026221,548

Institution ownership

CDNA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.16%4,814,709413.39MJun 29, 2026
State Street Corporation4.70%2,468,858211.98MJun 29, 2026
Vanguard Capital Management LLC4.18%2,197,475188.68MJun 29, 2026
Deerfield Management Company, L.P3.80%1,997,618171.52MJun 29, 2026
ARK Investment Management, LLC3.72%1,953,531167.73MJun 29, 2026
Boston Partners3.69%1,937,601166.36MJun 29, 2026

Fund ownership

CDNA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%1,554,868133.50MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.86%1,504,845129.21MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.2.61%1,373,550117.93MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,329,541114.15MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.51%1,321,241113.44MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.12%588,49450.53MJun 29, 2026